Drug-resistant cell lines in cancer
n recent years, the clinical landscape of cancer treatment has dramatically changed due to the development of new and refined therapeutic strategies. However, while patients may initially respond favourably to the available treatments, the development of resistance remains a major limitation. Experimental models of resistance in cancer are needed to study the underlying mechanisms and to develop effective approaches for the treatment resistant cancer. This post from Nature Communications shows how drug-resistant cancer cell lines can be developed and discusses how they can be used to address the issue of therapy resistance in cancer.
This poster is published in Nature Communications and freely available online thanks to the support from Cancer Tools.org.
Copyright © 2024, Springer Nature Limited. All rights reserved.
Contact:
Interdisciplinary Laboratory for Paediatric Tumour and Virus Research (IDL) at the Dr. Petra Joh-Research House
Prof. Dr. Jindrich Cinatl
j.cinatl@kinderkrebsstiftung-frankfurt.de
Prof. Dr. Martin Michaelis
m.michaelis@kinderkrebsstiftung-frankfurt.de
Phone +49 69 678665-72
School of Biosciences, University of Kent, Canterbury, UK
Prof. Dr. Martin Michaelis
Phone 44 01227 827804
m.michaelis@kent.ac.uk
